Federal AI Framework and Trump America Act Healthcare Analysis

The Trump administration released its National Policy Framework for Artificial Intelligence (March 20, 2026) outlining seven legislative priorities including federal preemption of state AI laws and intellectual property protections. Senator Marsha Blackburn introduced a discussion draft of the Trump America AI Act, which would codify Executive Order 14179 and establish a single federal rulebook for AI governance. Both proposals would introduce new liability frameworks, mandatory bias audits, copyright-based training data requirements, and transparency obligations affecting health care and life sciences organizations using AI applications.

SPIRE Program Six-Month Results in Washington County

The Oregon Department of Justice released a six-month progress report on the SPIRE (Special Projects: Investigate, Respond, Enforce) program, which embeds ODOJ investigators with Washington County law enforcement to target complex criminal activity. The program has served warrants on three illicit massage businesses, resulting in charges for soliciting prostitution and seizure of $18,000 in cash. Three individuals were referred to victim assistance services.

Swedish Witch Trial Commission Ended Prosecutions

The Library of Congress Law Blog published an educational post examining the Swedish witch trials and the 1676 Commission that ended prosecutions. The post describes Stora oväsendet (1667-1676), during which approximately 300 witches were killed and 400 total sentenced to death. The article references the 1734 Swedish legal code's provisions on witchcraft and superstition, which prescribed execution by strangulation for men and beheading with burning for women.

State Meat and Poultry Inspection Programs Information Collection

FSIS is requesting public comments on a revision to its State Meat and Poultry Inspection Programs information collection (OMB No. 0583-0170), adding 204 burden hours due to a new State inspection program. Comments are due June 1, 2026. This standard Paperwork Reduction Act submission has an approval expiration of August 31, 2026.

TransloadX Railroad Company Acquisition and Operation Exemption from CSX Transportation

The Surface Transportation Board granted TransloadX Railroad Company, Inc. an exemption under 49 CFR 1150.31 to lease and operate approximately 37.1 miles of railroad lines from CSX Transportation in Maine. TransloadX will become a Class III short line railroad operator upon the exemption becoming effective on April 16, 2026. The transaction involves the Augusta Branch (18.3 miles) and Bucksport Branch (18.8 miles).

Deputy Secretary Landau's Call with Icelandic Foreign Minister

Deputy Secretary of State Christopher Landau spoke with Icelandic Foreign Minister Thorgerdur Katrín Gunnarsdóttir on April 2, 2026. The call covered the situation in the Persian Gulf and Ukraine, as well as expanded bilateral cooperation on security and economic matters. Both leaders reaffirmed the long-standing US-Iceland partnership and expressed interest in strengthening ties.

U.S.-Italy Science and Technology Cooperation Joint Commission Statement

The U.S. Department of State announced outcomes from the 15th U.S.-Italy Joint Commission Meeting on Science and Technology Cooperation held April 1-2, 2026 in Washington, D.C. Both nations committed to deepened cooperation in quantum sciences, high-performance computing and AI, fission and fusion energy, biotechnology, and advanced materials. Italy announced significant funding for strategic joint research projects in 2027-2028, opening opportunities for U.S. research entities to compete for collaborations.

Boncresa biosimilar to Prolia approved for osteoporosis

FDA approved Boncresa (denosumab-b00) as a biosimilar to Prolia (denosumab), providing a new treatment option for patients with osteoporosis. The product is indicated for postmenopausal women, men, and patients with glucocorticoid-induced osteoporosis at high risk for fracture, as well as bone loss from hormone ablation therapy for cancer. Boncresa is administered as a 60 mg subcutaneous injection every 6 months.

Oziltus Biosimilar to XGEVA Approved for Bone Metastases and Multiple Myeloma

FDA approved Oziltus (denosumab-mobz), a biosimilar referencing XGEVA (denosumab), for prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors. The drug is also approved for giant cell tumor of bone and hypercalcemia of malignancy. Marketed by Amneal Pharmaceuticals LLC, this approval expands treatment options for bone-related oncology conditions.

Brandi Willis Ogden v. Charles B. Wayne Ogden - Civil Writ Denial

The Louisiana Court of Appeal, First Circuit denied an application for supervisory writs filed by Brandi Willis Ogden against Charles B. Wayne Ogden. The appellate court declined to review the 22nd Judicial District Court's ruling in St. Tammany Parish, Case No. 2023-13709. The single-page ruling affirms the lower court's decision with no written opinion.